I feel like in most other fields you would just focus on the the soluble MPMP modeling and become a provider to antibody companies, who would in turn sell their candidates off to a company specialized in pushing through clinical trials and approval. But instead it seems like biotech startups try to own the entire chain, as if they were J&J. Is that the case, and if so why do you think it is? Is biotech still too new and niche?
I will start by thanking Abhishaike Mahajan for his insightful article. I am pretty new to this, but I think this trying to own the entire chain in this case may be due to patenting issues ( actual reduction to practice and so on). But that's just a hunch on my part, and I am curious to know the answer to this one myself.
I feel like in most other fields you would just focus on the the soluble MPMP modeling and become a provider to antibody companies, who would in turn sell their candidates off to a company specialized in pushing through clinical trials and approval. But instead it seems like biotech startups try to own the entire chain, as if they were J&J. Is that the case, and if so why do you think it is? Is biotech still too new and niche?
I will start by thanking Abhishaike Mahajan for his insightful article. I am pretty new to this, but I think this trying to own the entire chain in this case may be due to patenting issues ( actual reduction to practice and so on). But that's just a hunch on my part, and I am curious to know the answer to this one myself.
The dumb obvious solution is to give these proteins an oil water interface by just using greasy test tubes.